RU2675370C2 - Способ выявления присутствия или отсутствия агрессивного рака предстательной железы - Google Patents

Способ выявления присутствия или отсутствия агрессивного рака предстательной железы Download PDF

Info

Publication number
RU2675370C2
RU2675370C2 RU2015124054A RU2015124054A RU2675370C2 RU 2675370 C2 RU2675370 C2 RU 2675370C2 RU 2015124054 A RU2015124054 A RU 2015124054A RU 2015124054 A RU2015124054 A RU 2015124054A RU 2675370 C2 RU2675370 C2 RU 2675370C2
Authority
RU
Russia
Prior art keywords
biomarkers
pca
category
snppc
combined value
Prior art date
Application number
RU2015124054A
Other languages
English (en)
Russian (ru)
Other versions
RU2015124054A (ru
Inventor
Хенрик ГРЕНБЕРГ
Мартин Эклунд
Original Assignee
Пхадиа Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пхадиа Аб filed Critical Пхадиа Аб
Publication of RU2015124054A publication Critical patent/RU2015124054A/ru
Application granted granted Critical
Publication of RU2675370C2 publication Critical patent/RU2675370C2/ru

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G01N33/575—
    • G01N33/57555—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
RU2015124054A 2012-11-20 2013-11-20 Способ выявления присутствия или отсутствия агрессивного рака предстательной железы RU2675370C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1251312 2012-11-20
SE1251312-3 2012-11-20
SE1350600 2013-05-16
SE1350600-1 2013-05-16
PCT/EP2013/074259 WO2014079865A1 (en) 2012-11-20 2013-11-20 Method for indicating a presence or non-presence of aggressive prostate cancer

Publications (2)

Publication Number Publication Date
RU2015124054A RU2015124054A (ru) 2017-01-10
RU2675370C2 true RU2675370C2 (ru) 2018-12-19

Family

ID=49619938

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015124054A RU2675370C2 (ru) 2012-11-20 2013-11-20 Способ выявления присутствия или отсутствия агрессивного рака предстательной железы

Country Status (14)

Country Link
US (1) US10431326B2 (enExample)
EP (2) EP2922967B1 (enExample)
JP (2) JP2016503301A (enExample)
KR (1) KR20150110477A (enExample)
AU (1) AU2013349801B2 (enExample)
BR (1) BR112015011359B1 (enExample)
CA (2) CA3092807C (enExample)
DK (1) DK2922967T3 (enExample)
ES (1) ES2667326T3 (enExample)
IL (1) IL238724A0 (enExample)
MY (1) MY182773A (enExample)
RU (1) RU2675370C2 (enExample)
WO (1) WO2014079865A1 (enExample)
ZA (1) ZA201503460B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2827104C1 (ru) * 2023-12-22 2024-09-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный медицинский университет им. В.И. Разумовского" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Саратовский ГМУ им. В.И. Разумовского Минздрава России) Способ прогнозирования риска развития рака предстательной железы

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013230167B2 (en) 2012-03-05 2018-05-24 Opko Diagnostics, Llc Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
US10428385B2 (en) 2012-11-20 2019-10-01 Phadia Ab Prognostic method for individuals with prostate cancer
AU2015230017B2 (en) 2014-03-11 2021-06-17 A3P Biomedical Ab Method for detecting a solid tumor cancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2015148979A1 (en) 2014-03-28 2015-10-01 Opko Diagnostics, Llc Compositons and methods related to diagnosis of prostate cancer
JP6749337B2 (ja) 2015-03-27 2020-09-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ 前立腺抗原標準およびその使用
US9858665B2 (en) * 2015-04-03 2018-01-02 Regents Of The University Of Minnesota Medical imaging device rendering predictive prostate cancer visualizations using quantitative multiparametric MRI models
SG11201708289TA (en) * 2015-04-29 2017-11-29 Opko Diagnostics Llc Compositions and methods for active surveillance of prostate cancer
WO2017164699A1 (ko) * 2016-03-24 2017-09-28 서울대학교병원 (분사무소) 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
ES2688213T3 (es) * 2016-07-15 2018-10-31 Proteomedix Ag Método para detectar proteínas en muestras humanas y usos de dichos métodos
WO2018141828A1 (en) 2017-02-01 2018-08-09 Phadia Ab Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics
KR102093453B1 (ko) * 2018-01-08 2020-03-25 (주)인실리코젠 체형 및 대사 감수성 snp 마커 및 진단정보 제공방법
JP7416723B2 (ja) 2018-01-22 2024-01-17 ファディア アクチボラゲット 分析結果の調和のための方法
IT201800021394A1 (it) * 2018-12-28 2020-06-28 Daniela Terracciano Metodo in vitro per la diagnosi del cancro alla prostata
US11633146B2 (en) 2019-01-04 2023-04-25 Regents Of The University Of Minnesota Automated co-registration of prostate MRI data
US11631171B2 (en) 2019-01-10 2023-04-18 Regents Of The University Of Minnesota Automated detection and annotation of prostate cancer on histopathology slides
CN109628564B (zh) * 2019-02-25 2022-02-01 北京市理化分析测试中心 一种用于检测snp多态性的引物组和利用引物组检测snp多态性的方法
KR102371654B1 (ko) * 2019-02-28 2022-03-08 주식회사 프로카젠 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102371655B1 (ko) * 2019-02-28 2022-03-08 주식회사 프로카젠 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102068666B1 (ko) * 2019-02-28 2020-02-11 주식회사 프로카젠 인종 별 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102068667B1 (ko) * 2019-02-28 2020-01-21 주식회사 프로카젠 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
IT202000029948A1 (it) * 2020-12-04 2022-06-04 Nib Biotec S R L Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età
JP7641532B2 (ja) * 2020-08-28 2025-03-07 国立研究開発法人理化学研究所 前立腺がんの検査方法
GB2599198B (en) * 2021-06-15 2022-12-07 A3P Biomedical Ab A method for determining an appropriate time interval for further diagnostic testing for prostate cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150515A1 (en) * 2010-06-01 2011-12-08 Universite Laval Prognostic markers for prostate cancer recurrence
US20120021925A1 (en) * 2009-01-19 2012-01-26 Miraculins, Inc. Diagnostic assays for prostate cancer using psp94 and psa biomarkers
WO2012031207A2 (en) * 2010-09-03 2012-03-08 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219840A1 (en) 2002-05-24 2003-11-27 Mikolajczyk Stephen D. Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
WO2010093939A2 (en) 2009-02-12 2010-08-19 Dana-Farber Cancer Institute, Inc. Predicting and treating prostate cancer
US20120202888A1 (en) 2010-10-08 2012-08-09 The Brigham And Women's Hospital, Inc. Biomarkers of prostate cancer and predicting mortality
US20120150032A1 (en) * 2010-12-13 2012-06-14 Julius Gudmundsson Sequence Variants Associated with Prostate Specific Antigen Levels
CA2871877A1 (en) 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
US10428385B2 (en) 2012-11-20 2019-10-01 Phadia Ab Prognostic method for individuals with prostate cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120021925A1 (en) * 2009-01-19 2012-01-26 Miraculins, Inc. Diagnostic assays for prostate cancer using psp94 and psa biomarkers
WO2011150515A1 (en) * 2010-06-01 2011-12-08 Universite Laval Prognostic markers for prostate cancer recurrence
WO2012031207A2 (en) * 2010-09-03 2012-03-08 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NGUYEN PL., et al., Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival.J Clin Oncol. 2010 Sep 1;28(25):3958-64. doi: 10.1200/JCO.2009.27.0793. Epub 2010 Aug 2. LIM U., et al., Susceptibility variants for obesity and colorectal cancer risk: the multiethnic cohort and PAGE studies.Int J Cancer. 2012 Sep 15;131(6):E1038-43. doi: 10.1002/ijc.27592. Epub 2012 Apr 30. STARK JR., et al., Toll-like receptor signaling pathway variants and prostate cancer mortality.Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1859-63. doi: 10.1158/1055-9965.EPI-08-0981. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2827104C1 (ru) * 2023-12-22 2024-09-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный медицинский университет им. В.И. Разумовского" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Саратовский ГМУ им. В.И. Разумовского Минздрава России) Способ прогнозирования риска развития рака предстательной железы

Also Published As

Publication number Publication date
CA2891392C (en) 2020-11-03
EP2922967A1 (en) 2015-09-30
CA3092807C (en) 2024-02-27
DK2922967T3 (en) 2018-04-16
CA2891392A1 (en) 2014-05-30
RU2015124054A (ru) 2017-01-10
BR112015011359A8 (pt) 2019-10-01
BR112015011359B1 (pt) 2022-12-06
ES2667326T3 (es) 2018-05-10
EP2922967B1 (en) 2018-01-03
KR20150110477A (ko) 2015-10-02
MY182773A (en) 2021-02-05
US10431326B2 (en) 2019-10-01
US20150317431A1 (en) 2015-11-05
ZA201503460B (en) 2018-11-28
CN105051206A (zh) 2015-11-11
CA3092807A1 (en) 2014-05-30
HK1215594A1 (en) 2016-09-02
BR112015011359A2 (pt) 2017-07-11
JP2019049559A (ja) 2019-03-28
EP3327146A1 (en) 2018-05-30
JP2016503301A (ja) 2016-02-04
AU2013349801B2 (en) 2019-03-07
WO2014079865A1 (en) 2014-05-30
IL238724A0 (en) 2015-06-30
AU2013349801A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
RU2675370C2 (ru) Способ выявления присутствия или отсутствия агрессивного рака предстательной железы
RU2669809C2 (ru) Способ прогноза для индивидуумов с раком предстательной железы
RU2720148C9 (ru) Способ обнаружения солидной злокачественной опухоли
JP2022179483A (ja) 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
CN105051206B (zh) 用于指示侵袭性前列腺癌的存在或不存在的方法
HK1215594B (en) Method for indicating a presence or non-presence of aggressive prostate cancer